Clinically Relevant Lymphoma Models with Key Mutations & Molecular Characteristics
Evaluate your Lymphoma drug candidates on our advanced in vivo screening platform, which features a comprehensive bank of 19 pretreated and treatment-naïve patient-derived xenograft (PDX) lymphoma models. Our carefully curated collection includes models treated with advanced cancer therapies like CAR-T, DICE, and EPOCH. Significantly, the CTG-3879 model featured in the screen is derived from a patient who experienced disease progression following treatment with a combination of lenalidomide and tafasitamab-cxix, an anti-CD19 antibody therapy.
Clinically Relevant Models
Living bank of 19 clinically relevant PDX models with key mutations and molecular characteristics.
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses
Champions' leading Lymphoma In Vivo Screen showcases 19 PDX models, each reflecting key clinical characteristics, mutations, and pretreatment history.
-
Includes advanced Lymphoma models pretreated with advanced cancer therapies such as CAR-T, DICE, and EPOCH.
-
Includes models with pretreatment resistance history to targeted treatments and the latest immunotherapies, such as lenalidomide and tafasitamab-cxix antibody therapy targeting CD19.
-
Complete model characterization (clinical data, NGS analysis, proteomics, phospho-proteomics, and more).
-
Several endpoint data options available including Flow Cytometry and IHC to quantify target expression and critical phenotypical changes (available upon request).
-
Terminal tumor collections for target validation is available upon request (Snap Frozen/FFPE)
-
No minimum to enroll & 50% off a Standard of Care Agent arm (selected by Champions)
Lymphoma In Vivo Screen Models Clinical and Molecular Characteristics:
These Lymphoma models are derived from distinct tumor types and encompass various tumor statuses (primary vs. metastatic), treatment histories (naive vs. pretreated), and mutation burdens.
Treatment responses of three Lymphoma PDX models, CTG-3064, CTG-3793, and CTG-3803, to standards-of-care.
Lymphoma In Vivo Screen PDX Models Mutation Clustering
Utilizing Lumin, our Clustering Heatmap tool is a web-based application designed to visually interpret and analyze complex data through interactive and shareable hierarchically clustered heatmaps.
-
Visualize expression signatures and the prevalence of driver mutations in each PDX model.
-
Gain profound insights by exploring RNA-seq, WES, proteomics, and phospho-proteomics datasets.
-
Harness quality data from extensive datasets to drive informed decision-making.